2005-2018年纽约州按社会决定因素分列的原发性酒精使用问题和阿片类药物使用障碍患者的阿片类依赖药物处方模式差异。

IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Journal of the American Pharmacists Association Pub Date : 2024-09-27 DOI:10.1016/j.japh.2024.102258
Chi-Hua Lu, Hsuan-Yun Su, Zackary Falls, David M. Jacobs, Qiuyi Zhang, Walter Gibson, Gail Jette, Debanjan Paul, Peter L. Elkin, Kenneth E. Leonard, Edward M. Bednarczyk
{"title":"2005-2018年纽约州按社会决定因素分列的原发性酒精使用问题和阿片类药物使用障碍患者的阿片类依赖药物处方模式差异。","authors":"Chi-Hua Lu,&nbsp;Hsuan-Yun Su,&nbsp;Zackary Falls,&nbsp;David M. Jacobs,&nbsp;Qiuyi Zhang,&nbsp;Walter Gibson,&nbsp;Gail Jette,&nbsp;Debanjan Paul,&nbsp;Peter L. Elkin,&nbsp;Kenneth E. Leonard,&nbsp;Edward M. Bednarczyk","doi":"10.1016/j.japh.2024.102258","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The increase in alcohol use problems and opioid use disorder (OUD) highlights the need for research on effective medication treatments for patients with dual diagnoses.</div></div><div><h3>Objectives</h3><div>This study analyzed trends and social disparities in prescribing OUD medications for patients who initially had alcohol use problems and later received their first OUD diagnosis.</div></div><div><h3>Methods</h3><div>This study used merged data from the New York State Office of Addiction Services and Supports and the Medicaid to analyze individuals aged 18 years and older who initially had primary alcohol use problems and later had OUD for the first time between 2005 and 2018. It examined the rates of new buprenorphine and naltrexone prescriptions across various demographic and socioeconomic groups.</div></div><div><h3>Results</h3><div>Among 27,029 clients, the average rate of new buprenorphine was 64.23 per 1000 clients (95% CI 61.30–67.15), with upward trends. The 18-35 age group had the highest buprenorphine utilization (111.48 per 1000 clients) and highest increase rates compared with other age groups. The white non-Hispanic group had the highest rates of buprenorphine (119.23 per 1000 clients) and showed larger increase over time compared with other race or ethnicity groups. Disabled patients showed slower increasing rates of buprenorphine than other groups. Upward trends were observed in naltrexone. All observed differences were statistically significant (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>Trends showed increased use of OUD medications, with varying rates of buprenorphine utilization across different ages, races, and employment statuses. Despite this, the rates of receiving new buprenorphine remained low, suggesting a need for innovative methods to expand access to treatments.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"65 1","pages":"Article 102258"},"PeriodicalIF":2.5000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Differences in prescribing patterns of opioid dependence drugs among patients with primary alcohol use problems and opioid use disorders within New York State by social determinant factors, 2005-2018\",\"authors\":\"Chi-Hua Lu,&nbsp;Hsuan-Yun Su,&nbsp;Zackary Falls,&nbsp;David M. Jacobs,&nbsp;Qiuyi Zhang,&nbsp;Walter Gibson,&nbsp;Gail Jette,&nbsp;Debanjan Paul,&nbsp;Peter L. Elkin,&nbsp;Kenneth E. Leonard,&nbsp;Edward M. Bednarczyk\",\"doi\":\"10.1016/j.japh.2024.102258\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The increase in alcohol use problems and opioid use disorder (OUD) highlights the need for research on effective medication treatments for patients with dual diagnoses.</div></div><div><h3>Objectives</h3><div>This study analyzed trends and social disparities in prescribing OUD medications for patients who initially had alcohol use problems and later received their first OUD diagnosis.</div></div><div><h3>Methods</h3><div>This study used merged data from the New York State Office of Addiction Services and Supports and the Medicaid to analyze individuals aged 18 years and older who initially had primary alcohol use problems and later had OUD for the first time between 2005 and 2018. It examined the rates of new buprenorphine and naltrexone prescriptions across various demographic and socioeconomic groups.</div></div><div><h3>Results</h3><div>Among 27,029 clients, the average rate of new buprenorphine was 64.23 per 1000 clients (95% CI 61.30–67.15), with upward trends. The 18-35 age group had the highest buprenorphine utilization (111.48 per 1000 clients) and highest increase rates compared with other age groups. The white non-Hispanic group had the highest rates of buprenorphine (119.23 per 1000 clients) and showed larger increase over time compared with other race or ethnicity groups. Disabled patients showed slower increasing rates of buprenorphine than other groups. Upward trends were observed in naltrexone. All observed differences were statistically significant (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>Trends showed increased use of OUD medications, with varying rates of buprenorphine utilization across different ages, races, and employment statuses. Despite this, the rates of receiving new buprenorphine remained low, suggesting a need for innovative methods to expand access to treatments.</div></div>\",\"PeriodicalId\":50015,\"journal\":{\"name\":\"Journal of the American Pharmacists Association\",\"volume\":\"65 1\",\"pages\":\"Article 102258\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Pharmacists Association\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1544319124002899\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Pharmacists Association","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1544319124002899","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:酒精使用问题和阿片类药物使用障碍(OUD)的增加凸显了研究双重诊断患者有效药物治疗的必要性:酒精使用问题和阿片类药物使用障碍(OUD)的增加凸显了对双重诊断患者进行有效药物治疗研究的必要性:本研究分析了为最初有酗酒问题、后来首次被诊断为阿片类药物使用障碍的患者开具阿片类药物处方的趋势和社会差异:本研究利用纽约州成瘾服务与支持办公室和医疗补助计划的合并数据,分析了 2005 年至 2018 年间年龄在 18 岁及以上、最初有主要酒精使用问题、后来首次出现 OUD 的个人。该研究考察了不同人口和社会经济群体中新开丁丙诺啡和纳曲酮处方的比例:在 27,029 名客户中,丁丙诺啡的平均新处方率为每千名客户 64.23(95% CI [61.30, 67.15]),且呈上升趋势。与其他年龄组相比,18-35 岁年龄组的丁丙诺啡使用率最高(每 1000 名客户 111.48 次),增长率也最高。非西班牙裔白人群体的丁丙诺啡使用率最高(每 1000 名客户 119.23 次),与其他种族/族裔群体相比,随着时间的推移,其使用率增幅更大。与其他群体相比,残疾患者使用丁丙诺啡的比例增长较慢。纳曲酮呈上升趋势。所有观察到的差异均具有统计学意义(PConclusions:趋势表明,OUD 药物的使用有所增加,不同年龄、种族和就业状况的丁丙诺啡使用率各不相同。尽管如此,接受新丁丙诺啡的比例仍然很低,这表明需要采用创新方法来扩大治疗范围。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Differences in prescribing patterns of opioid dependence drugs among patients with primary alcohol use problems and opioid use disorders within New York State by social determinant factors, 2005-2018

Background

The increase in alcohol use problems and opioid use disorder (OUD) highlights the need for research on effective medication treatments for patients with dual diagnoses.

Objectives

This study analyzed trends and social disparities in prescribing OUD medications for patients who initially had alcohol use problems and later received their first OUD diagnosis.

Methods

This study used merged data from the New York State Office of Addiction Services and Supports and the Medicaid to analyze individuals aged 18 years and older who initially had primary alcohol use problems and later had OUD for the first time between 2005 and 2018. It examined the rates of new buprenorphine and naltrexone prescriptions across various demographic and socioeconomic groups.

Results

Among 27,029 clients, the average rate of new buprenorphine was 64.23 per 1000 clients (95% CI 61.30–67.15), with upward trends. The 18-35 age group had the highest buprenorphine utilization (111.48 per 1000 clients) and highest increase rates compared with other age groups. The white non-Hispanic group had the highest rates of buprenorphine (119.23 per 1000 clients) and showed larger increase over time compared with other race or ethnicity groups. Disabled patients showed slower increasing rates of buprenorphine than other groups. Upward trends were observed in naltrexone. All observed differences were statistically significant (P < 0.05).

Conclusions

Trends showed increased use of OUD medications, with varying rates of buprenorphine utilization across different ages, races, and employment statuses. Despite this, the rates of receiving new buprenorphine remained low, suggesting a need for innovative methods to expand access to treatments.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.30
自引率
14.30%
发文量
336
审稿时长
46 days
期刊介绍: The Journal of the American Pharmacists Association is the official peer-reviewed journal of the American Pharmacists Association (APhA), providing information on pharmaceutical care, drug therapy, diseases and other health issues, trends in pharmacy practice and therapeutics, informed opinion, and original research. JAPhA publishes original research, reviews, experiences, and opinion articles that link science to contemporary pharmacy practice to improve patient care.
期刊最新文献
Implementing a Telemedicine-led Heart Failure Medication Regimen Optimization Clinic in Medically Underserved Heart Failure Populations. Exploring the pharmacist role in insomnia management and care provision: A scoping review. Long-Term Opioid Therapy in Older Adults: Incidence and Risk Factors Related to Patient Characteristics and Initial Opioid Dispensed. Pharmacists Enhance National Security through Medical Countermeasure Program Leadership. Barriers to and Facilitators of Buprenorphine Dispensing for Opioid Use Disorder: Evidence from Focus Groups in Appalachian Kentucky.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1